恒瑞医药获得瑞维鲁胺片药物临床试验批准通知书

Core Viewpoint - Heng Rui Medicine (600276.SH) has received approval from the National Medical Products Administration for the clinical trial of Rivoceranib tablets in combination with HS-20093 injection for prostate cancer treatment [1] Group 1: Product Development - Rivoceranib tablets are a second-generation AR inhibitor, which exhibit stronger AR inhibition compared to first-generation AR inhibitors and do not have agonistic effects [1] - The company’s Rivoceranib tablets were approved for market launch in 2022 for the treatment of high tumor burden metastatic hormone-sensitive prostate cancer (mHSPC) patients [1]